Ignite Creation Date:
2025-12-25 @ 1:44 AM
Ignite Modification Date:
2026-02-27 @ 10:39 AM
Study NCT ID:
NCT04100694
Status:
APPROVED_FOR_MARKETING
Last Update Posted:
2025-05-20
First Post:
2019-09-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Sponsor:
Merus N.V.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | NRG1 Fusion | View |
| None | Pancreatic Cancer | View |
| None | Non Small Cell Lung Cancer | View |
| None | Solid Tumor, Unspecified, Adult | View |
| None | Prostate Cancer | View |
| None | Head and Neck Cancer | View |
| None | Colorectal Cancer | View |
| None | Breast Cancer | View |
| None | Cholangiocarcinoma | View |
| None | Renal Cell Carcinoma | View |
| None | Unknown Primary Tumors | View |